Vascular endothelial growth factor (VEGF) signaling in tumour vascularization: Potential and challenges

Current Vascular Pharmacology

Volumn 15, Issue 4, 2017, Pages 339-351

  Siveen, Kodappully Sivaraman ^a   Prabhu, Kirti ^a   Krishnankutty, Roopesh ^a   Kuttikrishnan, Shilpa ^a   Tsakou, Magdalini ^a   Alali, Feras Q ^b   Dermime, Said ^a   Mohammad, Ramzi M ^a   Uddin, Shahab ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b Qatar University ^*  (Qatar)

Author keywords

Angiogenic balance; Anti VEGF therapy; Extracellular matrix; Food and drug administration; Tumour angiogenesis; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENIC FACTOR; ANGIOSTATIN; APTAMER; AXITINIB; BEVACIZUMAB; CEDIRANIB; CYCLOOXYGENASE 2; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 1; HEMOPEXIN; INTERLEUKIN 1; INTERLEUKIN 12; MOTESANIB; OSTEOPONTIN; PAZOPANIB; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR; RAMUCIRUMAB; SORAFENIB; THROMBOSPONDIN; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASOSTATIN; VASCULOTROPIN A;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG TARGETING; HUMAN; METASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; CHEMISTRY; DRUG EFFECTS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85016992320     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161115666170105124038     Document Type: Article

References (145)

1. Folkman J, D'Amore PA. Blood vessel formation: What is its molecular basis? Cell 1996; 87(7): 1153-55.
2. Veeravagu A, Hsu AR, Cai W, et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov 2007; 2(1): 59-71.
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6(4): 389-96.
4. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49(3): 507-21.
5. Papapetropoulos A, García-Cardeña G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100(12): 3131.
6. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69(Suppl 3): 4-10.
7. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380(6573): 435-39.
8. Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 1998; 252(3): 743-46.
9. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004; 10(4): 143-45.
10. Sainson RC, Johnston DA, Chu HC, et al. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 2008; 111(10): 4997-5007.
11. Carmeliet P, Lampugnani M-G, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98(2): 147-57.
12. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13(1): 9-22.
13. Dhar-Mascareno M, Mascareno E, Golde DW. Early Signaling by Vascular Endothelial Growth Factor and Placental Growth Factor in Human Bone Marrow-Derived Endothelial Cells Is Mediated by Superoxide. J Vasc Res 2009; 46(6): 601-08.
14. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10(7): 505-14.
15. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407(6801): 242-48.
16. Ferrara N, Carver Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380(6573): 439-42.
17. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
18. Vu TH, Shipley JM, Bergers G, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93(3): 411-22.
19. Pinedo H, Slamon DJ. Introduction translational research: The role of VEGF in tumor angiogenesis. Oncologist 2000; 5(Suppl 1): 1-2.
20. Nagy J, Chang S, Dvorak A, Dvorak H. Why are tumour blood vessels abnormal and why is it important to know & quest. Br J Cancer 2009; 100(6): 865-69.
21. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011; 37(1): 63-74.
22. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277(5322): 55-60.
23. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13(9): 1055-66.
24. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376(6535): 62-66.
25. Bouck N, Stellmach V, Hsu S. How tumors become angiogenic. Adv Cancer Res 1996; 69: 135-74.
26. Luttun A, Autiero M, Tjwa M, Carmeliet P. Genetic dissection of tumor angiogenesis: Are PlGF and VEGFR-1 novel anti-cancer targets? Biochim Biophys Acta, Rev Cancer 2004; 1654(1): 79-94.
27. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: Models and modulators. Int Rev Cytol 1995; 159: 113-60.
28. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta, Mol Cell Res 1994; 1221(2): 211-14.
29. Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of angiogenesis in solid tumours: An overview. Eur J Intern Med 2009; 20(7): 663-71.
30. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65(10): 3967-79.
31. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-76.
32. Brower V. Less is more. EMBO Rep 2003; 4(9): 831-34.
33. Terranova VP, DiFlorio R, Lyall RM, et al. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol 1985; 101(6): 2330-34.
34. Gospodarowicz D, Abraham J, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86(19): 7311-15.
35. Millauer B, Wizigmann-Voos S, Schnürch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72(6): 835-46.
36. Ross R. Platelet-derived growth factor. Lancet 1989; 333(8648): 1179-82.
37. Lindahl P, Johansson BR, Levéen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277(5323): 242-45.
38. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22(10): 1276-312.
39. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor α in human disease. N Engl J Med 2000; 342(18): 1350-58.
40. Lawrence DA. Transforming growth factor-beta: A general review. Eur Cytokine Netw 1996; 7(3): 363-74.
41. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Nat Acad Sci USA 1986; 83(12): 4167-71.
42. Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P. Anthocyanins and their gut metabolites reduce the adhesion of monocyte to TNFα-activated endothelial cells at physiologically relevant concentrations. J Cell Physiol 2009; 219(2): 449-58.
43. Wong ML, Prawira A, Kaye AH, Hovens CM. Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci 2009; 16(9): 1119-30.
44. Fiedler U, Augustin HG Angiopoietins: A link between angiogenesis and inflammation. Trends Immunol 2006; 27(12): 552-58.
45. Thomas M, Augustin HG. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 2009; 12(2): 125-37.
46. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000; 89(6): 1181-94.
47. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79(2): 315-28.
48. Harris A. Angiogenesis as a new target for cancer control. EJC 2003; 1(2): 1-12.
49. Gomez D, Alonso D, Yoshiji H, Thorgeirsson U. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997; 74(2): 111-22.
50. Giannelli G, Erriquez R, Fransvea E, et al. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 2004; 109(5): 782-85.
51. Murphy AN, Unsworth EJ, Stetler Stevenson WG. Tissue inhibitor of metalloproteinases2 inhibits bFGF induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157(2): 351-58.
52. Seo D-W, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003; 114(2): 171-80.
53. Kirsch M, Strasser J, Allende R, et al. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 1998; 58(20): 4654-59.
54. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2(6): 689-92.
55. Stack MS, Gately S, Bafetti LM, Enghild JJ. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrixenhanced plasminogen activation. Biochem J 1999; 340(1): 77-84.
56. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274(17): 11721-26.
57. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277-85.
58. Kim Y-M, Hwang S, Kim Y-M, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277(31): 27872-79.
59. Lawler J. Thrombospondin 1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6(1): 1-12.
60. Jiménez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6(1): 41-48.
61. Li X, Jiang L, Wang Y, et al. Inhibition of angiogenesis by a novel small peptide consisting of the active fragments of platelet factor-4 and vasostatin. Cancer Lett 2007; 256(1): 29-32.
62. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013; 13(12): 871-82.
63. Muller YA, Li B, Christinger HW, et al. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 1997; 94(14): 7192-97.
64. Suto K, Yamazaki Y, Morita T, Mizuno H. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms insight into selective VEGF binding to kinase insert domaincontaining receptor but not to FMS-like tyrosine kinase-1. J Biol Chem 2005; 280(3): 2126-31.
65. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling? In control of vascular function. Nat Rev Mol Cell Biol 2006; 7(5): 359-71.
66. Suarez SC, Pieren M, Cariolato L, et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 2006; 63(17): 2067-77.
67. Stalmans I. Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome. Verh K Acad Geneeskd Belg 2004; 67(4): 229-76.
68. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56(4): 549-80.
69. Poltorak Z, Cohen T, Sivan R, et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997; 272(11): 7151-58.
70. Ortéga N, Hutchings H, Plouët J. Signal relays in the VEGF system. Front Biosci 1999; 4: 141-52.
71. Plouët J, Moro F, Bertagnolli S, et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272(20): 13390-96.
72. Scrofani SD, Fabri LJ, Xu P, Maccarone P, Nash AD. Purification and refolding of vascular endothelial growth factor-B. Protein Sci 2000; 9(10): 2018-25.
73. Makinen T, Olofsson B, Karpanen T, et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem 1999; 274(30): 21217-22.
74. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996; 93(6): 2576-81.
75. Bellomo D, Headrick JP, Silins GU, et al. Mice lacking the vascular endothelial growth factor-B gene (VEGFB) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000; 86(2): 29-35.
76. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15(2): 290-98.
77. Witzenbichler B, Asahara T, Murohara T, et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998; 153(2): 381-94.
78. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5(1): 74-80.
79. Ogawa S, Oku A, Sawano A, et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998; 273(47): 31273-82.
80. Robinson DR, Wu Y-M, Lin S-F. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19(49): 5548-57.
81. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009; 90(3): 232-48.
82. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473(7347): 298-307.
83. Saito T, Takeda N, Amiya E, et al. VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing. FEBS Lett 2013; 587(14): 2179-85.
84. Man X, Yang X, Cai S, Yao Y, Zheng M. Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med 2006; 12(7-8): 127-36.
85. Nomura M, Yamagishi S-i, Harada S-i, et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995; 270(47): 28316-24.
86. Tasaki Y, Nishimura R, Shibaya M, et al. Expression of VEGF and its receptors in the bovine endometrium throughout the estrous cycle: effects of VEGF on prostaglandin production in endometrial cells. J Reprod Dev 2010; 56(2): 223-29.
87. Millauer B, Shawver LK, Plate KH, Risaui W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367(6463): 576-9.
88. Plate K, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993; 53(23): 5822-27.
89. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21(2): 154-65.
90. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92(8): 3566-70.
91. Carmeliet P, De Smet F, Loges S, Mazzone M. Branching morphogenesis and antiangiogenesis candidates: Tip cells lead the way. Nat Rev Clin Oncol 2009; 6(6): 315-26.
92. Le Bras B, Barallobre M-J, Homman-Ludiye J, et al. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. Nat Neurosci 2006; 9(3): 340-48.
93. Schmeisser A, Christoph M, Augstein A, et al. Apoptosis of human macrophages by Flt-4 signaling: Implications for atherosclerotic plaque pathology. Cardiovasc Res 2006; 71(4): 774-84.
94. Orlandini M, Spreafico A, Bardelli M, et al. Vascular endothelial growth factor-D activates VEGFR-3 expressed in osteoblasts inducing their differentiation. J Biol Chem 2006; 281(26): 17961-67.
95. Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor 1 in human cancer. Cancer 2010; 116(S4): 1027-32.
96. Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001; 97(3): 785-91.
97. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis a crucial target for anti-and pro-angiogenic therapies. Genes Cancer 2011; 2(12): 1097-105.
98. Schlessinger J, Lemmon MA. SH2 and PTB domains in tyrosine kinase signaling. Sci STKE 2003; 2003(191): 1212.
99. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci Signal 2001; 2001(112): 21.
100. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
101. Niu G, Chen X. Vascular endothelial growth factor as an antiangiogenic target for cancer therapy. Curr Drug Targets 2010; 11(8): 1000-17.
102. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60(7): 1878-86.
103. Arjaans M, Schroder CP, Oosting SF, et al. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: From bench to bedside. Oncotarget 2016; 7(16): 21247-58.
104. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10(6): 417-27.
105. Jain RK. Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol 2013; 31(17): 2205-18.
106. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev Cancer 2006; 6(11): 835-45.
107. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-42.
108. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57(20): 4593-9.
109. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88(12): 1979-86.
110. Lu D, Jimenez X, Zhang H, et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002; 97(3): 393-9.
111. Lu D, Shen J, Vil MD, et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 2003; 278(44): 43496-507.
112. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28(5): 780-7.
113. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5(2): 123-32.
114. Zhou B, Wang B. Pegaptanib for the treatment of age-related macular degeneration. Exp Eye Res 2006; 83(3): 615-9.
115. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99(17): 11393-8.
116. Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004; 10(10): 3327-32.
117. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006; 33(4): 407-20.
118. Ikezoe T, Nishioka C, Tasaka T, et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: Enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006; 5(10): 2522-30.
119. Rock EP, Goodman V, Jiang JX, et al. Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12(1): 107-13.
120. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099-109.
121. Hasskarl J. Sorafenib. Recent Results Cancer Res 2010; 184: 61-70.
122. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23(5): 965-72.
123. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Invest Drugs 2008; 9(12): 1324-35.
124. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trend Pharmacol Sci 2009; 30(12): 624-30.
125. Li J-L, Sainson RC, Oon CE, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011; 71(18): 6073-83.
126. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-50.
127. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-76.
128. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-34.
129. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378-90.
130. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005; 8(4): 299-309.
131. Dey N, De P, Brian L-J. Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors. Am J Transl Res 2015; 7(10): 1675-98.
132. Piao Y, Liang J, Holmes L, et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 2012; 14(11): 1379-92.
133. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Nat Acad Sci USA 2007; 104(43): 17069-74.
134. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11(1): 83-95.
135. Piao Y, Liang J, Holmes L, et al. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 2013; 19(16): 4392-403.
136. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 2009; 15(3): 167-70.
137. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15(3): 232-39.
138. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15(3): 220-31.
139. Okazaki T, Ebihara S, Asada M, et al. Granulocyte colonystimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+ CD11b+ cells in cancer animal models. Int Immunol 2006; 18(1): 1-9.
140. Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci USA 2008; 105(7): 2640-45.
141. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006; 124(1): 175-89.
142. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438(7069): 820-27.
143. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+ Gr1+ myeloid cells. Nat Biotechnol 2007; 25(8): 911-20.
144. Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: Basics for primary care providers. Cardiol Res Pract 2011; 2011: 816897.
145. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3(1): 24-40.